A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors (NCT07226349)
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: University of Alabama At Birmingham Hospital — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- University of Alabama At Birmingham Hospital — Birmingham, Alabama
- Yale Cancer Center — New Haven, Connecticut
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- The University of Texas Md Anderson Cancer Center — Houston, Texas
- Next Houston — Houston, Texas
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Blacktown Cancer and Haematology Centre — Blacktown, New South Wales
- Genesiscare St Leonards — St Leonards, New South Wales
- Icon Cancer Centre Wesley — Auchenflower, Queensland
- Cabrini Hospital Malvern — Malvern, Victoria
- Peter Maccallum Cancer Centre — Melbourne, Victoria
- One Clinical Research — Nedlands, Western Australia
- Cancer Hospital Chinese Academy of Medical Sciences — Beijing, Beijing Municipality
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) — Guangzhou, Guangdong
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei
- Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch — Wuhan, Hubei
- Jiangsu Province Hospital Longjiang Branch — Nanjing, Jiangsu
- Qilu Hospital of Shandong University — Jinan, Shandong
- Weifang Peoples Hospital — Weifang, Shandong
- Rigshospitalet — Copenhagen,
📞 Contact the Study Coordinator
Phone: (877) 828-5568
Email: clinicaltrials@beonemed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.